您的位置: 百康网 > 期刊 > 药学 > 《实验药学杂志》 > 2005年 > 2005年10月第20期 > 正文
New target for T regs
 本页关键词:T
2007-6-11 17:59:22

The natural killer (NK) cell is a new target for regulatory T (T reg) cell tyranny, according to a study on page 1075. Ghiringhelli and colleagues show that the antitumor activity of NK cells is snuffed out by T reg cells, allowing tumors to grow unchecked.

NK cells are innate immune cells that help destroy NK cell–sensitive tumors, such as melanomas and gastrointestinal tumors, which express activating ligands for these cells. The activation and antitumor functions of NK cells are triggered by the binding of these ligands to the activating receptor NKG2D on the NK cells. In many cancer patients, NK cell activity is hampered by the shedding of NKG2D ligands from tumor cells or by other unknown mechanisms.

This group recently showed that a drug that activates NK cells in patients with gastrointestinal cancer improved their prognoses. They now report that the patients who did not respond to this therapy had increased numbers of circulating T reg cells, whereas the patients who responded did not. The T reg cells from nonresponding patients prevented NK cells from killing tumor cells in vitro.

In mice, transfer of T reg cells blocked the killing capacity of NK cells. This inhibition depended on the expression of membrane-bound TGF-? on the T reg cells, which triggered the down-regulation of NKG2D on the NK cells. Thus TGF-?–induced inhibition of NK cell activation, which normally helps curtail inflammation and prevent autoimmunity, helps certain tumors avoid being recognized by these killer cells.

 



查询更多T相关信息在本站>>

  

《实验药学杂志》2005年10月第201卷第20期 

评论】【打印】【 】【关闭
相关文章
Pretargeted Anti–Carcinoembryonic-Antigen Radioimmunotherapy for Medullary Thyroid Carcinoma
Induction of Tolerance in Autoimmune Diseases Rather Than Cure of Cancer by Interleukin-2 Therapy
Optimal Selection of Individuals for BRCA Mutation Testing
Normal CA-125 and the Risk of Progression in Ovarian Cancer
Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma
Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors
Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group Comparing Quality of Life in Patients With Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carb
Phase III Trial of Intraperitoneal Therapy With Yttrium-90–Labeled HMFG1 Murine Monoclonal Antibody in Patients With Epithelial Ovarian Cancer After a Surgically Defined Complete Remission
Randomized Double-Blind Trial of Estrogen Replacement Therapy Versus Placebo in Stage I or II Endometrial Cancer: A Gynecologic Oncology Group Study